Urate-lowering therapy and the risk of developing type 2 diabetes mellitus in patients with gout (results of a prospective study)
Objective: to analyze the association between medications intake and the development of type 2 diabetes mellitus (T2DM) in patients with gout. Material and methods. The study included 444 patients with gout without T2DM. The median follow-up time was 5.9 [2.9; 8.7] years. The primary end point was...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2023-10-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/1480 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849691603197755392 |
|---|---|
| author | M. S. Eliseev O. V. Zhelyabina |
| author_facet | M. S. Eliseev O. V. Zhelyabina |
| author_sort | M. S. Eliseev |
| collection | DOAJ |
| description | Objective: to analyze the association between medications intake and the development of type 2 diabetes mellitus (T2DM) in patients with gout. Material and methods. The study included 444 patients with gout without T2DM. The median follow-up time was 5.9 [2.9; 8.7] years. The primary end point was the diagnosis of T2DM. At baseline, therapy was initiated or adjusted according to current guidelines. Medication use was recorded: allopurinol, febuxostat, diuretics, glucocorticoids (GC), canakinumab, for which the odds ratio (OR) of developing T2DM was calculated. Results and discussion. T2DM occurred in 108 (24.3 %) patients enrolled in the study. 405 patients completed the study. 311 (76.7 %) patients were taking urate-lowering drugs: 263 (90.7 %) allopurinol, 48 (9.3 %) febuxostat. The mean dose of allopurinol was 153.4 ± 28.4 mg/day, and that of febuxostat was 91.6 ± 12.1 mg/day. During treatment with febuxostat, the probability of developing T2DM was lower: OR 0.433 (95 % confidence interval, CI 0.188–0.996; p = 0.044). When diuretics were used OR was 2.212 (95 % CI 1.303–3.753; p = 0.003), GC – 1.566 (95 % CI 1.003–2.445; p = 0.048). Conclusion. Febuxostat use is associated with a lower likelihood of developing T2DM. |
| format | Article |
| id | doaj-art-391d98dabd604816a3feaf577ca8e395 |
| institution | DOAJ |
| issn | 1996-7012 2310-158X |
| language | Russian |
| publishDate | 2023-10-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj-art-391d98dabd604816a3feaf577ca8e3952025-08-20T03:20:59ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2023-10-01175737810.14412/1996-7012-2023-5-73-782620Urate-lowering therapy and the risk of developing type 2 diabetes mellitus in patients with gout (results of a prospective study)M. S. Eliseev0O. V. Zhelyabina1V.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyObjective: to analyze the association between medications intake and the development of type 2 diabetes mellitus (T2DM) in patients with gout. Material and methods. The study included 444 patients with gout without T2DM. The median follow-up time was 5.9 [2.9; 8.7] years. The primary end point was the diagnosis of T2DM. At baseline, therapy was initiated or adjusted according to current guidelines. Medication use was recorded: allopurinol, febuxostat, diuretics, glucocorticoids (GC), canakinumab, for which the odds ratio (OR) of developing T2DM was calculated. Results and discussion. T2DM occurred in 108 (24.3 %) patients enrolled in the study. 405 patients completed the study. 311 (76.7 %) patients were taking urate-lowering drugs: 263 (90.7 %) allopurinol, 48 (9.3 %) febuxostat. The mean dose of allopurinol was 153.4 ± 28.4 mg/day, and that of febuxostat was 91.6 ± 12.1 mg/day. During treatment with febuxostat, the probability of developing T2DM was lower: OR 0.433 (95 % confidence interval, CI 0.188–0.996; p = 0.044). When diuretics were used OR was 2.212 (95 % CI 1.303–3.753; p = 0.003), GC – 1.566 (95 % CI 1.003–2.445; p = 0.048). Conclusion. Febuxostat use is associated with a lower likelihood of developing T2DM.https://mrj.ima-press.net/mrj/article/view/1480type 2 diabetes mellitusgouturic acidurate-lowering therapyfebuxostat |
| spellingShingle | M. S. Eliseev O. V. Zhelyabina Urate-lowering therapy and the risk of developing type 2 diabetes mellitus in patients with gout (results of a prospective study) Современная ревматология type 2 diabetes mellitus gout uric acid urate-lowering therapy febuxostat |
| title | Urate-lowering therapy and the risk of developing type 2 diabetes mellitus in patients with gout (results of a prospective study) |
| title_full | Urate-lowering therapy and the risk of developing type 2 diabetes mellitus in patients with gout (results of a prospective study) |
| title_fullStr | Urate-lowering therapy and the risk of developing type 2 diabetes mellitus in patients with gout (results of a prospective study) |
| title_full_unstemmed | Urate-lowering therapy and the risk of developing type 2 diabetes mellitus in patients with gout (results of a prospective study) |
| title_short | Urate-lowering therapy and the risk of developing type 2 diabetes mellitus in patients with gout (results of a prospective study) |
| title_sort | urate lowering therapy and the risk of developing type 2 diabetes mellitus in patients with gout results of a prospective study |
| topic | type 2 diabetes mellitus gout uric acid urate-lowering therapy febuxostat |
| url | https://mrj.ima-press.net/mrj/article/view/1480 |
| work_keys_str_mv | AT mseliseev urateloweringtherapyandtheriskofdevelopingtype2diabetesmellitusinpatientswithgoutresultsofaprospectivestudy AT ovzhelyabina urateloweringtherapyandtheriskofdevelopingtype2diabetesmellitusinpatientswithgoutresultsofaprospectivestudy |